-
EP4469463
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4469463
| EP4469463 - RIFAMYCIN DERIVATIVES FOR THE TREATMENT OF DISEASES [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 26.09.2025 Database last updated on 19.05.2026 | |
| Former | Grant of patent is intended Status updated on 25.05.2025 | ||
| Former | Request for examination was made Status updated on 01.11.2024 | ||
| Former | The international publication has been made Status updated on 05.08.2023 | ||
| Former | unknown Status updated on 03.02.2023 | Most recent event Tooltip | 01.05.2026 | Lapse of the patent in a contracting state | published on 03.06.2026 [2026/23] | Applicant(s) | For all designated states BioVersys AG Hochbergerstrasse 60c 4057 Basel / CH | [2024/49] | Inventor(s) | 01 /
ANTRAYGUES, Kevin 59120 Loos / FR | 02 /
BOUROTTE, Marilyne 59840 Perenchies / FR | 03 /
DALE, Glenn E. 4053 Basel / CH | 04 /
DEFERT, Olivier 59000 Lille / FR | 05 /
GIOIA, Bruna 59800 Lille / FR | 06 /
GITZINGER, Marc 4057 Basel / CH | 07 /
LOCIURO, Sergio 4058 Basel / CH | 08 /
MAINGOT, Mathieu 59800 Lille / FR | 09 /
TREBOSC, Vincent 68680 Kembs-Loechlé / FR | 10 /
WILLAND, Nicolas 59800 Lille / FR | [2024/49] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [N/P] |
| Former [2024/49] | Latscha Schöllhorn Partner AG Grellingerstrasse 60 4052 Basel / CH | Application number, filing date | 23701975.7 | 27.01.2023 | [2024/49] | WO2023EP51991 | Priority number, date | EP20220154022 | 28.01.2022 Original published format: EP 22154022 | [2024/49] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023144297 | Date: | 03.08.2023 | Language: | EN | [2023/31] | Type: | A1 Application with search report | No.: | EP4469463 | Date: | 04.12.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.08.2023 takes the place of the publication of the European patent application. | [2024/49] | Type: | B1 Patent specification | No.: | EP4469463 | Date: | 29.10.2025 | Language: | EN | [2025/44] | Search report(s) | International search report - published on: | EP | 03.08.2023 | Classification | IPC: | C07D498/22, A61P31/04, A61K31/4188 | [2024/49] | CPC: |
C07D498/22 (EP,US);
A61K31/4188 (US);
A61P31/04 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/49]
| Extension states | BA | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | RIFAMYCINDERIVATE ZUR BEHANDLUNG VON KRANKHEITEN | [2024/49] | English: | RIFAMYCIN DERIVATIVES FOR THE TREATMENT OF DISEASES | [2024/49] | French: | DÉRIVÉS DE LA RIFAMYCINE POUR LE TRAITEMENT DE MALADIES | [2025/24] |
| Former [2024/49] | DÉRIVÉS DE RIFAMYCINE POUR TRAITER DES MALADIES | Entry into regional phase | 04.06.2024 | National basic fee paid | 04.06.2024 | Designation fee(s) paid | 04.06.2024 | Examination fee paid | Examination procedure | 04.06.2024 | Examination requested [2024/49] | 04.06.2024 | Date on which the examining division has become responsible | 28.02.2025 | Amendment by applicant (claims and/or description) | 26.05.2025 | Communication of intention to grant the patent | 17.09.2025 | Fee for grant paid | 17.09.2025 | Fee for publishing/printing paid | 17.09.2025 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 28.01.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 29.10.2025 | PL | 29.10.2025 | NO | 29.01.2026 | RS | 29.01.2026 | IS | 28.02.2026 | [2026/23] | Cited in | International search | [A] GARCA ANA-BELN ET AL: "Strong In Vitro Activities of Two New Rifabutin Analogs against Multidrug-Resistant Mycobacterium tuberculosis", vol. 54, no. 12, 1 December 2010 (2010-12-01), US, pages 5363 - 5365, XP055929413, ISSN: 0066-4804, Retrieved from the Internet DOI: http://dx.doi.org/10.1128/AAC.00149-10 | [A] FIGUEIREDO R ET AL: "Synthesis and evaluation of rifabutin analogs against Mycobacteriumavium and H"3"7Rv, MDR and NRP Mycobacterium tuberculosis", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 2, 15 January 2009 (2009-01-15), pages 503 - 511, XP025893420, ISSN: 0968-0896, [retrieved on 20090115], DOI: 10.1016/J.BMC.2008.12.006 DOI: http://dx.doi.org/10.1016/j.bmc.2008.12.006 | [A] BARLUENGA J ET AL: "New rifabutin analogs: Synthesis and biological activity against Mycobacterium tuberculosis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 16, no. 22, 15 November 2006 (2006-11-15), pages 5717 - 5722, XP027966071, ISSN: 0960-894X, [retrieved on 20061115] | [A] ZLOH MIRE ET AL: "Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoBS522L strain and display a different binding mode at the RNAP [beta]-subunit site compared to rifampicin", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 225, 1 December 2021 (2021-12-01), AMSTERDAM, NL, pages 113734, XP055929410, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113734 DOI: http://dx.doi.org/10.1016/j.ejmech.2021.113734 | by applicant | US5262564 | KUNIN, CLIN. INFECT. DIS., 1996 | FARRMANDELL, MED. CLIN. NORTH. AM., 1982 | THORNSBERRY ET AL., REV. INFECT. DIS.,, 1983 | HOOVER ET AL., DIAGN. MICROBIOL. INFECT. DIS., 1993 | KERRY ET AL., J. ANTIMICROB. CHEMOTHER., 1975 | AZIZ ET AL., ANTIMICROB. AGENTS CHEMOTHER., 2017 | DICK ET AL., ANTIMICROB. AGENTS CHEMOTHER., 2020 | LUNA ET AL., NAT. MICROBIOL., 2020 | TREBOSC ET AL., DRUG DISCOV. TODAY, 2021 | TREBOSC ET AL., J. ANTIMICROB. CHEMOTHER., vol. 75, no. 12, 2020, pages 3552 - 3562 | "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", March 2011, WILEY-VCH | T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY | E. L. ELIELS. H. WILENL. N. MANDER: "Stereochemistry of Organic Compounds", WILEY |